Illumina, Inc. (LON:0J8Z)
97.91
+1.94 (2.02%)
At close: Oct 30, 2025
Illumina Revenue
Illumina had revenue of $1.08B USD in the quarter ending September 28, 2025, with 0.37% growth. This brings the company's revenue in the last twelve months to $4.29B, down -2.32% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.29B
Revenue Growth
-2.32%
P/S Ratio
4.52
Revenue / Employee
$474.86K
Employees
9,030
Market Cap
14.46B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Illumina News
- 11 days ago - Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings - Seeking Alpha
- 17 days ago - Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights - PRNewsWire
- 17 days ago - Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - PRNewsWire
- 18 days ago - Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - PRNewsWire
- 25 days ago - Illumina (ILMN) Shares Cross Below 200 DMA - Nasdaq
- 25 days ago - Illumina (ILMN) Analyst Rating Update: Evercore ISI Lowers Price Target | ILMN Stock News - GuruFocus
- 25 days ago - Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Nasdaq
- 4 weeks ago - ILMN Stock Set to Benefit From the Launch of New BioInsight Division - Nasdaq